Symposium | BCMA-directed bispecific antibodies

During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on B-cell maturation antigen (BCMA)-directed bispecific antibodies in multiple myeloma (MM).

Bumma provided an overview of T-cell engagement in relapsed/ refractory MM (Figure 1), sharing the latest clinical trial data on single agents and combination therapies in MM, including BCMA-directed bispecific antibodies (Figure 2). Bumma highlighted patient-specific clinical factors, preferences, and access as determinants of treatment selection, then closed with an overview of strategies to effectively manage adverse events and infections associated with the use of bispecific antibodies.

Figure 1. T-cell engagement in RRMM* 

Ab, antibody; BCMA, B-cell maturation antigen; BM, bone marrow; CAR, chimeric antigen receptor; FcRH5, Fc receptor-homolog 5; GC, germinal center; GPRC5D, G protein–coupled receptor class C group 5 member D; IFN, Interferon;  IL, interleukin; MM, multiple myeloma; NK, natural killer; PC, plasma cell; RR, relapsed/refractory; scFv, single-chain fragment variable; SLAM, signaling lymphocytic activation molecule; TNF, tumor necrosis factor.
*Adapted from Cho, et al.¹

Figure 2. Summary of patient characteristics and topline data from clinical trials of bispecific antibody combinations* 

AE, adverse event; C, cycle; CRS, cytokine release syndrome; dara, daratumumab; elran, elranatamab; len, lenalidomide; SC, subcutaneous; tec, teclistamab; QW, every week; Q2W, biweekly.
*Data from Dholaria, et al.²; Searle, et al.³; Grosicki, et al.⁴

This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.